Shandong Langnuo Pharmaceutical Co. Ltd.

The main purpose of the study is to study the pharmacokinetics of the test preparation Perindopril Amlodipine Tablets (III) (Specifications: 10 mg: 5 mg, produced by Shandong Langnuo Pharmaceutical Co., Ltd.) and the reference preparation Perindopril Amlodipine Tablets (III) (Kesoda®, Specifications: 10 mg: 5 mg, produced by Servier (Ireland) Industries Ltd.) in healthy adult participants after a single oral administration under fasting conditions, and to evaluate the bioequivalence of the two preparations when taken orally under fasting conditions. Secondary purpose of the study is to evaluate the safety of the test preparation Perindopril Amlodipine Tablets (III) (Specifications: 10 mg: 5 mg) and the reference preparation Perindopril Amlodipine Tablets (III) (Kesoda®, Specifications: 10 mg: 5 mg) in healthy adult participants.

Primary objective: To compare the differences in absorption extent and rate of ilaprazole enteric-coated tablets (5 mg) developed by Shandong Langnuo Pharmaceutical Co., Ltd. and ilaprazole enteric-coated tablets (5 mg, trade name: Yilian) certified by Livzon Pharmaceutical Factory of Livzon Group in healthy adults under fasting and postprandial administration conditions, and to evaluate their bioequivalence. Secondary objective: To evaluate the safety of ilaprazole enteric-coated tablets (5 mg) developed by Shandong Langnuo Pharmaceutical Co., Ltd. and ilaprazole enteric-coated tablets (5 mg, trade name: Yilian) certified by Livzon Pharmaceutical Factory of Livzon Group in healthy adults under fasting and postprandial administration conditions.

The in vivo glucose pharmacokinetics produced by oral administration of sucrose was used as the control group to investigate the changes in the in vivo glucose pharmacokinetics produced by oral administration of 3 tablets of voglibose orodisintegrating tablets (test preparation T, specification: 0.2 mg) provided by Shandong Langnuo Pharmaceutical Co., Ltd. or 3 tablets of voglibose orodisintegrating tablets (reference preparation R, trade name: Basen®, specification: 0.2 mg) certified by Teva Takeda Yakuhin Ltd. and sucrose in healthy Chinese subjects. The effects of the two voglibose preparations on glucose kinetics were used as pharmacodynamic indicators to evaluate the bioequivalence between the two preparations.